Physician profile
Thomas E Sabalaske
NPI 1831161561
$10,696.39
in general payments reported to CMS, 2019-2025
48 companies · $2,162 in 2025
The $2,162 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $1,329 · 2021: $1,635 · 2022: $950 · 2023: $1,821 · 2024: $1,587 · 2025: $2,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,550 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,550.38 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,528.68 | 2019-2025 | |
| Abbvie INC. | $1,022.64 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $1,011.21 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,005.74 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $937.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $746.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $534.95 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $384.37 | 2019-2021 | |
| Amgen INC. | $317.89 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.44 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $292.40 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Abbott Laboratories | $235.84 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $221.15 | 2019-2025 | Spravato |
| Exact Sciences Corporation | $197.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $180.01 | 2019-2025 | Zoryve |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sabalaske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.